Prolonged survival in bi-allelic TP53-Mutated (TP53ᵐᵘᵗ ) MDS subjects treated with oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

ASTX727-03: Phase 1 study evaluating oral Decitabine/Cedazuridine (ASTX727) low-dose (LD) in lower-risk Myelodysplastic Syndromes (LR-MDS) patients

Treatment patterns and characteristics among patients with Myelodysplastic Syndromes initiating oral Decitabine and Cedazuridine or intravenous/subcutaneous hypomethylating agents in a real-world setting